[go: up one dir, main page]

PE20140629A1 - Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos - Google Patents

Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos

Info

Publication number
PE20140629A1
PE20140629A1 PE2013002002A PE2013002002A PE20140629A1 PE 20140629 A1 PE20140629 A1 PE 20140629A1 PE 2013002002 A PE2013002002 A PE 2013002002A PE 2013002002 A PE2013002002 A PE 2013002002A PE 20140629 A1 PE20140629 A1 PE 20140629A1
Authority
PE
Peru
Prior art keywords
phenyl
methyl
isoxazole
preparation
isoxazol
Prior art date
Application number
PE2013002002A
Other languages
English (en)
Inventor
Dong Yeon Kim
Dae Jin Cho
Gong Yeal Lee
Hong Youb Kim
Seok Hun Woo
Hae Un Lee
Choong Am Ahn
Seung Bin Yoon
Original Assignee
Il Yang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46514985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140629(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Il Yang Pharm Co Ltd filed Critical Il Yang Pharm Co Ltd
Publication of PE20140629A1 publication Critical patent/PE20140629A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE FENIL-ISOXAZOL DE FORMULA (1) DONDE R1, R2 Y R3 SON CADA UNO H, HALOGENO, ALQUILO INFERIOR O ALCOXI INFERIOR OPCIONALMENTE SUSTITUIDOS CON HALOGENO; R4 ES METILO O AMINA; R8 ES UN COMPUESTO DE FORMULA 2 O 3, EN DONDE R5, R6 Y R7 SON CADA UNO H, ALQUILO INFERIOR, HIDROXI, HALOGENO, ENTRE OTROS; R9 ES ALQUILO INFERIOR. SON COMPUESTOS PREFERIDOS: (4-(3-METOXIFENIL)PIPERAZINA-1-IL)(5-METIL-3-(2-(TRIFLUOROMETIL)FENIL)ISOXAZOL-4-IL)METANONA; (4-(2-FLUOROFENIL)PIPERAZINA-1-IL)(5-METIL-3-(2-(TRIFLUOROMETIL)FENIL)ISOXAZOL-4-IL)METANONA; (4-(3,4-DICLOROFENIL)PIPERAZINA-1-IL)(5-METIL-3-(2-(TRIFLUOROMETIL)FENIL)ISOXAZOL-4-IL)METANONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DEL VIRUS DE LA INFLUENZA
PE2013002002A 2011-04-19 2012-03-30 Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos PE20140629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110036172A KR101369584B1 (ko) 2011-04-19 2011-04-19 페닐-이속사졸 유도체 및 그의 제조방법

Publications (1)

Publication Number Publication Date
PE20140629A1 true PE20140629A1 (es) 2014-05-22

Family

ID=46514985

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002002A PE20140629A1 (es) 2011-04-19 2012-03-30 Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos

Country Status (21)

Country Link
US (1) US9132126B2 (es)
EP (1) EP2699566B1 (es)
JP (1) JP5833143B2 (es)
KR (1) KR101369584B1 (es)
CN (1) CN103313982B (es)
AR (1) AR086029A1 (es)
AU (1) AU2012246914B2 (es)
CA (1) CA2824757A1 (es)
CL (1) CL2013001910A1 (es)
CO (1) CO6771432A2 (es)
EA (1) EA022336B1 (es)
IL (1) IL227711A0 (es)
MX (1) MX340098B (es)
PE (1) PE20140629A1 (es)
PH (1) PH12013501883A1 (es)
SA (1) SA112330457B1 (es)
SG (1) SG192134A1 (es)
TW (1) TWI434836B (es)
UY (1) UY34023A (es)
WO (1) WO2012144752A1 (es)
ZA (1) ZA201305277B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
CA3052353A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
JP7019727B2 (ja) * 2017-02-08 2022-02-15 バイオトロン リミティッド インフルエンザの治療方法
TWI765323B (zh) * 2019-08-22 2022-05-21 大陸商四川海思科製藥有限公司 抗流感病毒化合物及其製備方法和用途
CN111704587B (zh) * 2020-06-29 2023-04-07 遵义医科大学 一种三氟甲基化1,3-噁嗪类化合物的合成方法
CN114349746A (zh) * 2020-11-19 2022-04-15 中国医学科学院医药生物技术研究所 一种含有4-氟苯基片段的吡啶类化合物及其制备方法和应用、药物组合物
JP2024506000A (ja) 2021-02-04 2024-02-08 四川海思科制▲薬▼有限公司 Ｈａ阻害剤化合物の塩及び結晶形

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8427618D0 (en) * 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
RU2181357C2 (ru) 1995-02-27 2002-04-20 Джилид Сайэнс, Инк. Композиция селективных ингибиторов вирусных или бактериальных нейраминидаз (варианты), соединение и способ лечения или профилактики заболевания гриппом
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
AU2002337843A1 (en) 2001-10-12 2003-04-22 Onconova Therapeutics, Inc. Processes for the preparation of substituted isoxazoles and 2-isoxazolines
MXPA04012959A (es) 2002-06-29 2005-05-16 Zentaris Gmbh Arilcarbonilpiperacinas y heteroarilcarbonilpiperacinas y su uso para tratamiento de enfermedades de tumor benigno y maligno.
AU2003232650A1 (en) 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
KR20050051729A (ko) 2003-11-28 2005-06-02 일양약품주식회사 사이클로 옥시게나제-2 억제제인 페닐 헤테로사이클의제조방법
CN1687075A (zh) * 2005-03-24 2005-10-26 天津药物研究院 3－苯基异噁唑－5－甲酰胺基取代β－内酰胺类衍生物及其用途
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
WO2009084024A2 (en) 2007-11-02 2009-07-09 Glenmark Generics Limited A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
US20090192326A1 (en) 2007-11-13 2009-07-30 Nurit Perlman Preparation of sitagliptin intermediate
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
KR101044880B1 (ko) 2008-06-12 2011-06-28 일양약품주식회사 항궤양제 화합물의 합성에 유용한 중간체의 제조방법
KR20100021321A (ko) 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
US20100297079A1 (en) * 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
WO2011015037A1 (en) * 2009-08-05 2011-02-10 The University Of Hongkong Antiviral compounds and methods of making and using there of cross reference to related applications
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
JP5902172B2 (ja) 2010-09-08 2016-04-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 広範囲のインフルエンザ抗ウイルス薬としての新規ピペラジン類似体
ES2564257T3 (es) 2010-09-28 2016-03-21 Bristol-Myers Squibb Company Nuevos análogos de piperazina con grupos heteroarilo sustituidos como antivirales de amplio espectro de la gripe
KR101956586B1 (ko) 2012-03-27 2019-03-11 일양약품주식회사 약제학적 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
ZA201305277B (en) 2014-09-25
TW201309658A (zh) 2013-03-01
EP2699566A4 (en) 2014-09-03
IL227711A0 (en) 2013-09-30
JP5833143B2 (ja) 2015-12-16
KR101369584B1 (ko) 2014-03-06
CA2824757A1 (en) 2012-10-26
EP2699566B1 (en) 2017-02-22
EA022336B1 (ru) 2015-12-30
HK1188998A1 (zh) 2014-05-23
EA201300805A1 (ru) 2013-11-29
CN103313982A (zh) 2013-09-18
AU2012246914B2 (en) 2015-09-24
CO6771432A2 (es) 2013-10-15
SG192134A1 (en) 2013-08-30
MX2013007661A (es) 2013-08-12
US9132126B2 (en) 2015-09-15
EP2699566A1 (en) 2014-02-26
CL2013001910A1 (es) 2014-04-21
NZ613314A (en) 2015-09-25
CN103313982B (zh) 2016-02-03
PH12013501883A1 (en) 2019-06-03
JP2014503601A (ja) 2014-02-13
WO2012144752A1 (en) 2012-10-26
UY34023A (es) 2012-06-29
TWI434836B (zh) 2014-04-21
US20140031364A1 (en) 2014-01-30
AU2012246914A1 (en) 2013-08-15
MX340098B (es) 2016-06-27
AR086029A1 (es) 2013-11-13
KR20120118665A (ko) 2012-10-29
SA112330457B1 (ar) 2015-08-19

Similar Documents

Publication Publication Date Title
PE20140629A1 (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos
PH12016501440A1 (en) Novel heterocyclic compounds
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
UA109792C2 (uk) Індоли як противірусні агенти відносно респіраторного синтиціального вірусу
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR054799A1 (es) Derivados de oxindol
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20141698A1 (es) Proceso para la preparacion de derivados de l-alanina protegidos
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
EA201590205A1 (ru) N-алкил 2-(дизамещенные)алкиниладенозин-5-уронамиды в качестве а-агонистов
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.

Legal Events

Date Code Title Description
FC Refusal